Medline Sales Soar in Public Debut, But Profits Feel the Squeeze

NORTHFIELD, IL – February 25, 2026 – In its inaugural financial report as a publicly traded company, Medline Inc. (Nasdaq: MDLN) today revealed a story of robust expansion shadowed by significant cost pressures. The medical-surgical supply giant reported impressive full-year 2025 sales of $28.4 billion, an 11.5% jump from the prior year, fueled by strong customer acquisition. However, this top-line success was tempered by a notable decline in profitability, with fourth-quarter net income falling 37.7%.

The results provide the first detailed glimpse into the financial health of the healthcare behemoth following its landmark Initial Public Offering in late 2025. The company attributed the profit squeeze to a combination of higher costs for goods sold due to tariffs, strategic investments in its workforce, and one-time expenses related to its public debut.

Despite the headwinds, Medline’s leadership projected confidence. “We delivered strong fourth quarter results, concluding a successful 2025 with $2.4 billion in total new customer signings,” said Jim Boyle, Chief Executive Officer of Medline. “Becoming a public company amplifies our voice and strengthens our foundation by enabling continued investments to drive growth and deliver greater value to customers. We expect our momentum to continue.”

A Tale of Two Ledgers

Medline's financial statements paint a dual picture of aggressive growth and mounting costs. For the fourth quarter ended December 31, 2025, net sales surged 14.8% to $7.8 billion. Yet, net income for the same period plummeted to $180 million from $289 million in Q4 2024. The full-year figures followed a similar, albeit less severe, pattern, with net income dipping 3.6% to $1.2 billion despite the $2.9 billion increase in annual revenue.

The primary culprits, as outlined by the company, were external economic forces and internal strategic decisions. Persistent tariffs on imported goods directly inflated the cost of goods sold, eroding gross margins. Simultaneously, Medline ramped up operating expenses, investing in a larger workforce to support its expanding customer base and absorbing substantial legal, accounting, and advisory fees associated with its IPO—the largest public offering of 2025, which raised over $6.2 billion.

Adjusted EBITDA, a non-GAAP measure that excludes interest, taxes, depreciation, amortization, and other specific costs, remained more stable. For the full year, it grew 3.2% to nearly $3.5 billion, suggesting the core operational performance remains strong when one-time and non-cash expenses are stripped out.

Wall Street's Warm Welcome

Despite the mixed bottom-line results, the market’s reception to Medline since its December 17, 2025, IPO has been largely positive. After pricing at $29 per share, the stock surged on its first day of trading, and initial analyst coverage has been bullish. Observers point to investor confidence in Medline's long-term strategy and dominant market position, viewing the current profit pressures as manageable growing pains for a newly public entity.

A key part of that strategy involves using the substantial proceeds from the IPO to deleverage its balance sheet. The company took on significant debt following its $34 billion leveraged buyout in 2021 by a private equity consortium. By paying down this debt, Medline is expected to reduce future interest expenses, thereby improving financial margins and freeing up cash flow for further investment and growth initiatives.

The Engine Room: Supply Chain and Strategic Investments

The engine driving Medline's formidable sales growth is its vast and sophisticated operational network. The company is the largest provider of medical-surgical products in the nation, and its performance was bolstered by strong growth in both its Medline Brand and Supply Chain Solutions segments. The latter saw a particularly sharp 17.6% increase in net sales during the fourth quarter, highlighting the increasing reliance of health systems on Medline for logistics and operational efficiency.

CEO Jim Boyle pointed to the company’s “unmatched distribution footprint” as a core competitive advantage. Medline has been aggressively investing in this area, pouring capital into automating its sprawling distribution centers and expanding its kitting manufacturing facilities. These investments are designed to enhance supply chain resilience and efficiency, a critical value proposition for hospitals and clinics navigating their own operational challenges.

This organic growth is complemented by a shrewd acquisition strategy. In the past year, Medline has integrated key businesses, including United Medco and Ecolab's surgical solutions division, to broaden its product portfolio and deepen its market penetration. These moves solidify its competitive standing against rivals like Cardinal Health and McKesson.

Navigating the Path Ahead

Looking forward, Medline has issued optimistic guidance for 2026. The company projects organic sales growth of 8% to 9% and anticipates Adjusted EBITDA to land between $3.5 billion and $3.6 billion. This forecast signals a belief that its powerful sales momentum and strong customer relationships will continue to outweigh the persistent cost challenges.

However, the path is not without risk. The forward-looking statements in the company’s report acknowledge a host of potential headwinds, including global macroeconomic uncertainty, inflationary pressures on labor and transportation, and the unpredictable nature of global trade policies and tariffs. The company's ability to navigate these external factors while continuing to integrate new technologies and expand its operational capacity will be critical to meeting its ambitious targets and delivering value as a public company.